SCHEMBL6779963

SCHEMBL6779963

CC(C)(C)OC(=O)COc1cccc(C(Nc2cccc(C(=N)N)c2)C(=O)NCC(=O)N2CCN(c3ccc(F)cc3F)CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 7/20 0.41
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GRM5 P41594 2/20 0.36
PARP1 P09874 1/20 0.36
PRSS1 P07477 3/20 0.36
F2 P00734 1/20 0.36
ENPP2 Q13822 1/20 0.36
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777513 0.92 F10 (0.45) F10ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL6897423 0.85 F10 (0.48) F10KMT2AGRM5PARP1PRSS1
SCHEMBL6778082 0.83 F10 (0.42) F10ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL6779135 0.81 TSHR (0.44) F10ALDH1A1LMNAMAPTMEN1
SCHEMBL6777481 0.80 ITGB3 (0.41) F10ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL6783740 0.79 ENPP2 (0.46) F10ALDH1A1MAPTMEN1KMT2A
SCHEMBL6774678 0.76 NPC1 (0.47) ALDH1A1SMN1; SMN2LMNAMAPTMEN1
SCHEMBL6780268 0.75 F10 (0.46) F10ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL6780280 0.75 LMNA (0.47) F10ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL6778302 0.74 POLB (0.45) F10ALDH1A1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794507-B2 Compounds that inhibit factor Xa activity MORPHOCHEM AG (DE) 2004-09-21 US disclosed
US-20030153510-A1 Novel compounds inhibiting factor xa activity CAPPI MICHAEL W (DE) 2003-08-14 US disclosed
EP-1311473-A2 NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY Morphochem AG (DE) 2003-05-21 EP disclosed
WO-2002016312-A2 NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY MORPHOCHEM AG (DE) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153510-A1 Novel compounds inhibiting factor xa activity SERPINC1, F11, TFPI F10 6/4885ALDH1A1 1037/4885SMN1; SMN2 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.